Talis Biomedical Corporation
TLIS · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $73 | $151 | $76 |
| % Growth | -100% | -51.7% | 98.7% | – |
| Cost of Goods Sold | $84 | $268 | $622 | $6 |
| Gross Profit | -$84 | -$195 | -$471 | $70 |
| % Margin | – | -267.1% | -311.9% | 92.1% |
| R&D Expenses | $1,601 | $2,533 | $8,041 | $8,302 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $7,977 | $6,418 | $5,988 | $8,803 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1,084 | $0 | $0 | $0 |
| Operating Expenses | $8,494 | $8,951 | $14,029 | $17,041 |
| Operating Income | -$9,578 | -$9,146 | -$14,500 | -$16,971 |
| % Margin | – | -12,528.8% | -9,602.6% | -22,330.3% |
| Other Income/Exp. Net | $729 | -$3,889 | $1,040 | $1,289 |
| Pre-Tax Income | -$8,849 | -$13,035 | -$13,460 | -$15,682 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8,849 | -$13,035 | -$13,460 | -$15,682 |
| % Margin | – | -17,856.2% | -8,913.9% | -20,634.2% |
| EPS | -4.86 | -7.15 | -7.4 | -8.62 |
| % Growth | 32% | 3.4% | 14.2% | – |
| EPS Diluted | -4.86 | -7.15 | -7.4 | -8.62 |
| Weighted Avg Shares Out | 1,822 | 1,822 | 1,820 | 1,819 |
| Weighted Avg Shares Out Dil | 1,822 | 1,822 | 1,820 | 1,819 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $1,166 | $0 |
| Depreciation & Amortization | $84 | $262 | $211 | $658 |
| EBITDA | -$9,494 | -$13,855 | -$14,289 | -$16,377 |
| % Margin | – | -18,979.5% | -9,462.9% | -21,548.7% |